Product
tremelimumab
1 clinical trial
1 indication
Indication
MelanomaClinical trial
A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients With Advanced MelanomaStatus: Completed, Estimated PCD: 2023-06-19